Curated news and analysis on clinical trials, drug approvals, and medical research.
Helus Pharma announced publication in Nature Medicine of Phase 2a trial results showing its short-acting psychedelic SPL026 met its primary endpoint with significant reductions in depressive symptoms at two weeks in moderate-to-severe MDD patients. The company also appointed a new SVP of Medical Affairs and is advancing HLP003 (Breakthrough Therapy Designation from FDA) and HLP004 in its pipeline.
Two securities class action lawsuits have been filed against NASDAQ-listed biopharmaceutical companies Ultragenyx and Vistagen. Both cases allege defendants made misleading statements about clinical trial results for key drug programs. Investors face deadlines in March and April 2026 to request lead plaintiff status.
Australia's Medical Research Future Fund is investing billions across multiple health research areas, including $100 million for arthritis research over 10 years, AU$22.9 million for dementia projects, and $436 million in 209 grants for Indigenous health research since 2017.
Takeda Pharmaceutical Company has announced updates on two ongoing neuroscience clinical trials: a Phase 2 study of TAK-360 for narcolepsy and a Phase 3 study of vortioxetine for major depressive disorder in Japanese teens. Both trials are randomized, triple-blind, and currently recruiting patients.
Japan's health ministry panel is reviewing two regenerative cell therapies for Parkinson's disease and heart failure, testing the country's push to build a domestic cell-based treatment industry. Japan's cell culture market is projected to reach USD 2.34 billion by 2031, driven by government support and favorable regulatory pathways. Australian firm Cartherics secured a Japanese patent for its iPSC-based immune cell therapies.
Recent research identifies hidden systemic inflammation in primary ciliary dyskinesia via oral swab and confirms asthma biologics do not increase respiratory infection risk in pediatric patients.
Long-term data from ASCO 2026 shows the personalized cancer vaccine Intismeran Autogene, combined with Keytruda, reduces recurrence or death risk by 49% in high-risk melanoma patients. Developed by MSD and Moderna, the vaccine uses AI to select neoantigens from a patient's tumor and mRNA technology to create a personalized treatment. The results signal a major advance for a field that had struggled for decades, spurring similar development efforts by other companies.
Milwaukee County has suspended four detention employees amid a drug smuggling investigation at the Community Reintegration Center, while Cook County Jail has uncovered a new smuggling technique involving narcotics-soaked books mailed from bookstores. Cook County invested over $2 million in detection technology to combat contraband in detention facilities.
Disc Medicine has agreed with the FDA to resubmit bitopertin for rare blood disorder erythropoietic protoporphyria, with the agency allowing the Phase 3 APOLLO trial to support a new filing. The agreement follows a February rejection and could lead to a mid-2027 decision. Disc has implemented workforce cuts and its CFO sold shares amid the regulatory setback.
Advances in precision mental health research include TMS findings published in Nature Molecular Psychiatry showing targeted brain stimulation can address specific depression and anxiety symptoms, the launch of the three-year GlobalMinds NHS genomic study analyzing 49,000 DNA samples, and the new $1 million Wellcome Prize for Mental Health Science.
Newport Police arrested four people after a month-long drug investigation culminated in a search warrant execution. Authorities seized cocaine laced with fentanyl and thousands of dollars in cash. All four suspects are expected in court Wednesday afternoon.
The Arizona Department of Housing awarded $2.5 million in tax credits for the Stone and Speedway Phase I project in Tucson, building 44 affordable units and 12 market-rate units. The $63 million development is the first phase of a two-phase project that will ultimately provide 119 units.
The U.S. cardiovascular drugs market is projected to reach $37.03 billion by 2035, growing at a CAGR of 2.68%. Europe's anticoagulants market is expected to reach $23.68 billion by 2033, expanding at a CAGR of 8.22%.
Two separate clinical trials have reported advances in cancer care. An oral drug combination of decitabine-cedazuridine and venetoclax showed efficacy in older patients with acute myeloid leukemia, with a 47% complete response rate in a phase 2b trial. A separate randomized controlled trial found that delaying pegfilgrastim administration to 72 hours post-chemotherapy significantly reduced bone pain in women with stage I–III breast cancer.
China's biotech overseas technology transfer agreements reached $137.7 billion in 2025, nearly ten times the 2021 figure, as global drugmakers rush to acquire Chinese candidates. BeiGene's Brukinsa surpassed $4 billion in global sales, while Pfizer agreed to a deal with Innovent Biologics worth up to $10.5 billion. U.S. lawmakers are raising security concerns about growing dependence on Chinese biotech.
Onco-Innovations has begun scaling production of A83B4C63, the API in its lead cancer drug ONC010, to kilogram quantities at Dalton Pharma Services' Toronto facility to support IND-enabling studies. The company's subsidiary Inka Health signed AI research agreements with AstraZeneca and GlaxoSmithKline, and plans a first-in-human study in 2026 pending a pre-IND meeting with the FDA.
A Washington federal judge declined to block a state law expanding 340B drug pricing discounts, rejecting Novartis and AbbVie's arguments that it illegally adds to their obligations under the federal program aimed at protecting low-income patients.
Twenty years after HPV vaccine approval, head and neck cancers have become the most common HPV-related cancer with 16,000 cases annually. The incidence tripled from 2000 to 2017, primarily affecting men in their 40s to 60s. Vaccination rates among teens reached approximately 77-79% for at least one dose in 2024.
Rare diseases affect an estimated 25-30 million Americans, yet 95% lack FDA-approved treatments. Families affected by conditions like SLC6A1-related disorders and Anti-IgLON5 Autoimmune Encephalitis voice concerns about drug pricing policies that could slow medical innovation. Advocates urge lawmakers to protect research investment while sharing stories of diagnostic challenges and treatment breakthroughs.
FDA announced a pilot program in April 2026 to enable real-time data review during clinical trials, aiming to significantly reduce drug approval timelines. Industry experts emphasized the benefits of direct data capture and AI-driven site selection while cautioning about potential accuracy concerns with early signal detection.
